HOME ABOUT CONTACT PREVIOUS ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Intelligent Sensor Informs You to Change a Diaper via SMS       » University of Manchester & A*STAR ongoing partnership- Joint PhD programme       » Philippines Healthcare & New Digital Platform, MyDoc.       » Tapping on ASEAN'S Healthcare Opportunities through Singapore       » ASEAN: The New Playing Field for Global Medical Device Companies       » The Burden of Great Potential: the ASEAN Economic Community & Biopharmaceuticals       » When there is no Queen in the house, Asian Hive Bees Avoid Risky Foraging for Reproduction       » XELJANZTM (Tofacitinib Citrate), A new class of treatment for Rheumatoid Arthritis Approved in Singapore      
EYE ON CHINA
Guo Guangchang Enters the Field of Medical Tumour Treatment

On September 3, 2013, Shanghai Fosun Pharmaceutical (Group) Co. Ltd. officially signed a strategic cooperation agreement with Guangzhou Nanyang Tumour Hospital and acquired a 50 percent stake in the hospital. The cooperation makes Guangzhou Nanyang Tumour Hospital the major platform of Fosun Pharm in the field of international high-end tumour therapy.

The ancestral home of Guo Guangchang, chairman of Fosun Group since 1994, is in Dongyang, Zhejiang province. He graduated from the Department of Philosophy of Fudan University and received an MBA from Fudan University in 1989. As Fosun has invested in many fields such as the insurance industry, the New York Times described the company as a mini Berkshire Hathaway Inc. And the Financial Times called Guo Guangchang "China's Buffett." Guo Guangchang is a member of the 9th national committee of CPPCC, a member of the 10th Central Committee of China Democratic League, and also a 10th and 11th NPC member in 2003 and 2008.

What makes this financial giant choose tumour therapy as one of his strategic investments? It's true that the increasing number of tumour patients in China and the world is an important cause for attracting capital, but not everyone worships money. Quite a few entrepreneurs still cherish the ideal of benefitting society. Besides business cooperation, Guo Guangchang has common views and an understanding of the ideals of Guangzhou Nanyang Tumour Hospital. In a 2010 charity conference, executive president of Nanyang Hospital Yasuka Miyaji said, "We need more money, not only for developing more professional and perfect medical services but also for the education of tumour prevention. We plan to set up a cancer fund in order to help poor tumour patients."

"I do not invest in companies, but people" is a well-known saying in the capital investment field. It may sound pretentious, but it's the personality, quality and operational philosophy of enterprise leaders that helps the investor to make a final decision.

Another reason for Guo Guangchang's investment in Guangzhou Nanyang Tumour Hospital lies in the expert team, technological advantages, internationalized service level and international influence of Guangzhou Nanyang Tumour Hospital. Sun Yan, one of the founders of the hospital, also started China's Medical Oncology and is a member of the Chinese Academy of Engineering. The team also includes Luo Pengfei in the tumour minimally invasive treatment center, a world renowned chief expert in that field, and Professor Li Peiwen, an expert in the combined treatment of traditional Chinese medicine and western medicine.

Guangzhou Nanyang Tumour Hospital also has a high degree of internationalization. With more than 20 years of development, it has become one of the most popular Chinese hospitals for patients around the world. More than 80 percent of patients are from the U.S., Australia, Indonesia, Malaysia, the Philippines, Singapore, Vietnam, and more. The Japanese management system and unique specialty of the hospital are other reasons that attracted Guo Guangchang.

Source: PR Newswire

Click here for the complete issue.

EDITORS' CHOICE  

Credits to: American Chemical Society
COLUMNS  

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy